AQR Capital Management
MLTX icon

AQR Capital Management’s MoonLake Immunotherapeutics MLTX Stock Holding History

AQR Capital Management’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.99M Buy
358,884
+312,699
+677% +$5.67M ﹤0.01% 1792
2026
Q1 		$861K Buy
46,185
+13,299
+40% +$220K ﹤0.01% 2853
2025
Q4 		$433K Buy
+32,886
New +$388K ﹤0.01% 2987
2024
Q2 		– Sell
-5,858
Closed -$294K – 2647
2024
Q1 		$294K Sell
5,858
-630
-10% -$34.2K ﹤0.01% 2136
2023
Q4 		$392K Buy
+6,488
New +$334K ﹤0.01% 1977

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

AQR Capital Management's MLTX Position: Q2 2026 in Review

AQR Capital Management increased its MoonLake Immunotherapeutics (MLTX) stake by 677% in Q2 2026, buying an estimated $5.67M and bringing the position to 358,884 shares worth $6.99M. The position accounts for ﹤0.01% of the portfolio, ranked #1792.

AQR Capital Management first reported a position in MLTX in Q4 2023 and has held it in 5 quarters since. 173 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

  • AQR Capital Management held 358,884 shares of MoonLake Immunotherapeutics worth $6.99M as of Q2 2026.
  • AQR Capital Management bought 312,699 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $5.67M.
  • MoonLake Immunotherapeutics made up ﹤0.01% of AQR Capital Management's portfolio in Q2 2026, its #1792 holding.
  • AQR Capital Management first reported a position in MoonLake Immunotherapeutics in Q4 2023 and has held it in 5 quarters since.
  • 173 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.